August 6, 2012 | Four House Democrats aim to close loopholes in the U.S. government's clinical trial reporting requirements to ensure that all human studies are publicly disclosed online. Current rules aren't robust enough, says group leader Rep. Edward Markey (D-Mass.), senior member of the Energy & Commerce Committee, particularly with regard to certain studies overseas.  

The proposed Trial & Experimental Studies Transparency Act would require medical device and drug makers to report all studies and results publicly through the government's registry, ClinicalTrials.gov, if the studies are used to support an FDA application. Mass Device